Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure

Cardiovascular Drugs and Therapy

Volumn 16, Issue 3, 2002, Pages 195-201

  Cittadini, Antonio ^a   Casaburi, Cosma ^a   Monti, Maria Gaia ^a   Di Gianni, Angela ^a   Serpico, Raffaella ^a   Scherillo, Giovanna ^a   Saldamarco, Lavinia ^a   Vanasia, Massimo ^b   Saccà, Luigi ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b GiEnne Pharma   (Italy)

Author keywords

Heart failure; Myocardial infarction; Potassium canrenoate; Reactive fibrosis

Indexed keywords

CANRENONE; CANRENONE GAMMA CYCLODEXTRIN; COLLAGEN; GAMMA CYCLODEXTRIN; MINERALOCORTICOID ANTAGONIST; PLACEBO; SPIRONOLACTONE; UNCLASSIFIED DRUG; ALDOSTERONE; ALDOSTERONE ANTAGONIST; CYCLODEXTRIN; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA-CYCLODEXTRIN; HYDROXYPROLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE ASSOCIATION; DRESSLER SYNDROME; DRUG EFFECT; HEART CATHETERIZATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEMODYNAMICS; METABOLISM; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CANRENONE; COLLAGEN; CYCLODEXTRINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMYOCARDIAL FIBROSIS; GAMMA-CYCLODEXTRINS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HYDROXYPROLINE; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT;

EID: 0036437740     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020640203862     Document Type: Article

References (22)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Meal 1999;341:709-717.
2. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A.
3. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000;102:2700-2706.
4. Bishop JE, Greenbaum R, Gibson DG, Yacoub M, Laurent GJ. Enhanced deposition of predominantly type I collagen in myocardial disease. J Mol Cell Cardiol 1990;22:1157-1165.
5. Wei S, Chow LTC, Shum IOL, Qin L, Sanderson JE. Left and right ventricular collagen type I-III ratios and remodeling post-myocardial infarction. J Cardiac Failure 1999;5:117-126.
6. Cittadini A, Grossman JD, Napoli R, et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997;29:1109-1116.
7. Mazzi V. Manuale di Tecniche Istologiche e Istochimiche. Padova, PD: Piccin, 1977.
8. Junqueira LCU, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue section. Histochem J 1979;11:445-447.
9. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-512.
10. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: Beneficial effects of long-term therapy with Captopril. Circulation 1985;72:406-412.
11. Grimm D, Kromer EP. Growth hormone and interstitial fibrosis. Cardiovasc Res 1999;43:254.
12. Grimm D, Cameron D, Griese DP, Riegger GAJ, Kromer EP. Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovasc Res 1998;40:297-306.
13. Van Kerckhoven R, Kalkman EAJ, Saxena PR, Schoemaker RG. Altered cardiac collagen and associated changes in diastolic function of infracted rat hearts. Cardiovasc Res 2000;46:316-323.
14. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991;69:107-115.
15. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportion of this aminoacid. Arch Biochem Biophys 1961;93:440-447.
16. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive Angiotensin II in human plasma. Hypertension 1985;71:I-1-I-7.
17. Pikering JG, Boughner DR. Fibrosis in the transplanted heart and this relation to donor ischemic time: Assessment with polarized light microscopy and digital image analysis. Circulation 1990;81:949-958.
18. Swynghendauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262.
19. Bauersachs J, Fraccarollo D, Ertl G, Grenz N, Wehling M, Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: Mechanistic evidence to support RALES. Circulation 2000;102:2325-2328.
20. Su JZ, Chen SC, Wu KG, et al. Effects of perindopril, propanolol, and dihydrochlorothiazide on cardiovascular remodeling in spontaneously hypertensive rats. Zhongguo Yao Li Xue Bao 1999;20:923-928.
21. Frohlich ED. Local hemodynamic changes in hypertension: Insights for therapeutic preservation of target organs. Hypertension 2001;38:1388-1394.
22. Silvestre J-S, Heymes C, Oubenaïssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effects of Angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-2701.